USD 2.17
(-0.46%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 66.02 Million USD | -30.27% |
2022 | 94.68 Million USD | -13.86% |
2021 | 109.92 Million USD | 3.64% |
2020 | 106.06 Million USD | 52.66% |
2019 | 69.47 Million USD | 28.93% |
2018 | 53.88 Million USD | 28.88% |
2017 | 41.81 Million USD | 29.94% |
2016 | 32.17 Million USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 13.82 Million USD | -9.3% |
2024 Q1 | 15.24 Million USD | 7.91% |
2023 Q4 | 14.12 Million USD | -9.02% |
2023 Q2 | 17.01 Million USD | -12.05% |
2023 Q1 | 19.34 Million USD | -8.21% |
2023 Q3 | 15.52 Million USD | -8.75% |
2023 FY | 66.02 Million USD | -30.27% |
2022 Q4 | 21.07 Million USD | -5.56% |
2022 Q1 | 27.82 Million USD | 9.8% |
2022 FY | 94.68 Million USD | -13.86% |
2022 Q2 | 23.46 Million USD | -15.67% |
2022 Q3 | 22.31 Million USD | -4.89% |
2021 FY | 109.92 Million USD | 3.64% |
2021 Q3 | 31.7 Million USD | 21.91% |
2021 Q2 | 26 Million USD | -3.2% |
2021 Q1 | 26.86 Million USD | -18.64% |
2021 Q4 | 25.34 Million USD | -20.07% |
2020 FY | 106.06 Million USD | 52.66% |
2020 Q4 | 33.02 Million USD | 23.58% |
2020 Q1 | 21.93 Million USD | 18.03% |
2020 Q3 | 26.72 Million USD | 9.61% |
2020 Q2 | 24.38 Million USD | 11.17% |
2019 Q1 | 17.31 Million USD | 10.34% |
2019 Q4 | 18.58 Million USD | 12.94% |
2019 Q3 | 16.45 Million USD | -3.97% |
2019 Q2 | 17.13 Million USD | -1.05% |
2019 FY | 69.47 Million USD | 28.93% |
2018 Q2 | 13.2 Million USD | 4.35% |
2018 FY | 53.88 Million USD | 28.88% |
2018 Q4 | 15.69 Million USD | 27.28% |
2018 Q1 | 12.65 Million USD | 6.9% |
2018 Q3 | 12.32 Million USD | -6.68% |
2017 Q3 | 9.82 Million USD | -4.43% |
2017 Q4 | 11.84 Million USD | 20.48% |
2017 FY | 41.81 Million USD | 29.94% |
2017 Q1 | 10.15 Million USD | 0.0% |
2017 Q2 | 10.28 Million USD | 1.23% |
2016 FY | 32.17 Million USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Abbott Laboratories | 15.71 Billion USD | 99.58% |
Allurion Technologies Inc. | 120.57 Million USD | 45.242% |
Artivion, Inc. | 223.43 Million USD | 70.45% |
Avanos Medical, Inc. | 375.5 Million USD | 82.417% |
Butterfly Network, Inc. | 162.46 Million USD | 59.361% |
Butterfly Network, Inc. | 162.46 Million USD | 59.361% |
Bio-Rad Laboratories, Inc. | 1.04 Billion USD | 93.697% |
Boston Scientific Corporation | 7.47 Billion USD | 99.117% |
Perspective Therapeutics, Inc. | 17.42 Million USD | -278.888% |
CONMED Corporation | 564.24 Million USD | 88.298% |
Edwards Lifesciences Corporation | 3.09 Billion USD | 97.864% |
Paragon 28, Inc. | 210.1 Million USD | 68.574% |
Glaukos Corporation | 367.83 Million USD | 82.05% |
Globus Medical, Inc. | 887.16 Million USD | 92.558% |
Inspire Medical Systems, Inc. | 568.49 Million USD | 88.386% |
Integer Holdings Corporation | 250.95 Million USD | 73.691% |
Medtronic plc | 16.12 Billion USD | 99.591% |
Nevro Corp. | 389.36 Million USD | 83.043% |
Owlet, Inc. | 51.21 Million USD | -28.907% |
Penumbra, Inc. | 590.87 Million USD | 88.826% |
Vicarious Surgical Inc. | 80.66 Million USD | 18.15% |
Smith & Nephew plc | 3.46 Billion USD | 98.096% |
Sonendo, Inc. | 68.46 Million USD | 3.564% |
STERIS plc | 1.4 Billion USD | 95.285% |
Stryker Corporation | 9.2 Billion USD | 99.283% |
Zimmer Biomet Holdings, Inc. | 3.27 Billion USD | 97.985% |